Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

NCT00666653 ·Status: COMPLETED ·Phase: PHASE1

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

NCT01097421 ·Status: COMPLETED

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523 ·Status: COMPLETED ·Phase: PHASE3

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

NCT00096720 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

NCT02172573 ·Status: COMPLETED ·Phase: PHASE3

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300 ·Status: COMPLETED ·Phase: PHASE4

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

NCT02177357 ·Status: COMPLETED ·Phase: PHASE3

Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease

NCT00240409 ·Status: COMPLETED ·Phase: PHASE3

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

NCT02236728 ·Status: COMPLETED

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

NCT00297778 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

NCT01191944 ·Status: COMPLETED ·Phase: PHASE3

Pivotal Study in Advanced Parkinsons Disease Patients

NCT00466167 ·Status: COMPLETED ·Phase: PHASE3

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

NCT00560508 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

NCT03019289 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease

NCT02231905 ·Status: COMPLETED ·Phase: PHASE4

Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice

NCT01061567 ·Status: COMPLETED

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

NCT00558025 ·Status: COMPLETED ·Phase: PHASE3

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

NCT01361009 ·Status: COMPLETED

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

NCT01673724 ·Status: COMPLETED ·Phase: PHASE4

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

NCT04377945 ·Status: TERMINATED ·Phase: PHASE2

The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

NCT01470859 ·Status: COMPLETED ·Phase: NA

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

NCT00321854 ·Status: COMPLETED ·Phase: PHASE4

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

NCT00651183 ·Status: COMPLETED

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

NCT03854019 ·Status: COMPLETED ·Phase: PHASE3